Search
FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement
We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).
Read moreEducational Travel Grants
EHA wants to facilitate participation in the Annual Congress for hematologists, researchers and practitioners from lower and middle-income countries.
Read moreThe European Parliament adopts the Regulation on Substances of Human Origins (SoHO)
On April 24, the European Parliament gave its final endorsement to the regulation on Substances of Human Origin (SoHO).
Read moreEHA-SPH joint membership
Save up to €50 by becoming a joint member of EHA and the Sociedade Portuguesa de Hematologia. We've joined forces with the Sociedade Portuguesa de Hematologia (SPH) to offer a special joint membership deal during 2024.
Read moreEHA-SPSHTM joint membership
Save up to €75 by becoming a joint member of EHA and the Scientific and Practical Society of Hematologists and Transfusiologists from the Republic of Moldova.
Read more